Invesco’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,690
| Closed | -$9.56K | – | 3798 |
|
|
2025
Q1 | $9.56K | Sell |
1,690
-50
| -3% | -$640 | ﹤0.01% | 3756 |
|
|
2024
Q4 | $36.7K | Buy |
1,740
+128
| +8% | +$2.94K | ﹤0.01% | 3717 |
|
|
2024
Q3 | $43.4K | Sell |
1,612
-8,293
| -84% | -$244K | ﹤0.01% | 3700 |
|
|
2024
Q2 | $282K | Buy |
9,905
+4,172
| +73% | +$146K | ﹤0.01% | 3525 |
|
|
2024
Q1 | $243K | Buy |
5,733
+1,133
| +25% | +$50.9K | ﹤0.01% | 3586 |
|
|
2023
Q4 | $246K | Buy |
4,600
+816
| +22% | +$36.8K | ﹤0.01% | 3495 |
|
|
2023
Q3 | $163K | Buy |
3,784
+1,787
| +89% | +$82.5K | ﹤0.01% | 3646 |
|
|
2023
Q2 | $110K | Buy |
+1,997
| New | +$110K | ﹤0.01% | 3710 |
|
|
2022
Q2 | – | Sell |
-1,441
| Closed | -$89K | – | 4081 |
|
|
2022
Q1 | $89K | Sell |
1,441
-3,919
| -73% | -$232K | ﹤0.01% | 3877 |
|
|
2021
Q4 | $378K | Sell |
5,360
-1,408
| -21% | -$100K | ﹤0.01% | 3508 |
|
|
2021
Q3 | $473K | Buy |
6,768
+781
| +13% | +$62.2K | ﹤0.01% | 3452 |
|
|
2021
Q2 | $499K | Sell |
5,987
-1,044
| -15% | -$73.9K | ﹤0.01% | 3425 |
|
|
2021
Q1 | $383K | Sell |
7,031
-996
| -12% | -$48.5K | ﹤0.01% | 3449 |
|
|
2020
Q4 | $344K | Buy |
8,027
+1,573
| +24% | +$58.7K | ﹤0.01% | 3362 |
|
|
2020
Q3 | $194K | Sell |
6,454
-153
| -2% | -$5.15K | ﹤0.01% | 3468 |
|
|
2020
Q2 | $205K | Buy |
6,607
+907
| +16% | +$24.4K | ﹤0.01% | 3465 |
|
|
2020
Q1 | $126K | Buy |
+5,700
| New | +$154K | ﹤0.01% | 3518 |
|
|
2018
Q4 | – | Sell |
-1,852
| Closed | -$97K | – | 3843 |
|
|
2018
Q3 | $97K | Sell |
1,852
-73
| -4% | -$4.1K | ﹤0.01% | 3788 |
|
|
2018
Q2 | $103K | Buy |
1,925
+924
| +92% | +$47.3K | ﹤0.01% | 3773 |
|
|
2018
Q1 | $50K | Buy |
+1,001
| New | +$44.9K | ﹤0.01% | 3683 |
|
|
2017
Q1 | – | Sell |
-5,703
| Closed | -$174K | – | 3722 |
|
|
2016
Q4 | $174K | Sell |
5,703
-83
| -1% | -$2.11K | ﹤0.01% | 3579 |
|
|
2016
Q3 | $157K | Buy |
5,786
+1,118
| +24% | +$31K | ﹤0.01% | 3566 |
|
|
2016
Q2 | $134K | Sell |
4,668
-200
| -4% | -$6.36K | ﹤0.01% | 3604 |
|
|
2016
Q1 | $147K | Buy |
4,868
+3,249
| +201% | +$92.1K | ﹤0.01% | 3616 |
|
|
2015
Q4 | $56K | Buy |
+1,619
| New | +$55.4K | ﹤0.01% | 3686 |
|
|
2015
Q3 | – | Sell |
-104
| Closed | -$6K | – | 3870 |
|
|
2015
Q2 | $6K | Buy |
+104
| New | +$5.92K | ﹤0.01% | 4119 |
|
|
2013
Q4 | – | Sell |
-857
| Closed | -$34K | – | 4343 |
|
|
2013
Q3 | $34K | Hold |
857
| – | – | ﹤0.01% | 4118 |
|
|
2013
Q2 | $31K | Buy |
+857
| New | +$32.8K | ﹤0.01% | 4091 |
|
Other funds holding HBIO
AE
HP
GIM
MIM
Invesco's HBIO Position: Q2 2025 in Review
Invesco sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 1,690 shares — an estimated $9.56K sold.
Invesco first reported a position in HBIO in Q2 2013 and held it in 28 quarters. The position peaked at $499K in Q2 2021. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.
- Invesco reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
- Invesco sold 1,690 Harvard Bioscience shares in Q2 2025, an estimated $9.56K.
- Invesco first reported a position in Harvard Bioscience in Q2 2013 and held it in 28 quarters.
- Invesco's Harvard Bioscience position peaked at $499K in Q2 2021.
- 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.
Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.